Equity Overview
Price & Market Data
Price: $4.27
Daily Change: -$0.01 / 0.23%
Range: $4.16 - $4.39
Market Cap: $664,636,224
Volume: 654,306
Performance Metrics
1 Week: 4.01%
1 Month: -25.13%
3 Months: 23.91%
6 Months: 41.56%
1 Year: 140.2%
YTD: 26.11%
Company Details
Employees: 394
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.